Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE
ConclusionReal-world ubrogepant use with an anti-CGRP monoclonal antibody was associated with MPR, RNF, satisfaction, and acute treatment optimization. (Source: Neurology and Therapy)
Source: Neurology and Therapy - November 1, 2023 Category: Neurology Source Type: research
Evaluating Elements of the Care Partner Experience in Individuals Who Care for People with Alzheimer's Disease Across the Severity Spectrum
ConclusionsPersons living with AD require increasing levels of care along the spectrum of disease, and even individuals with early disease need care from partners. Early interventions that slow progression of AD and programs that improve family function may have beneficial impact on the experiences of care partners for recipients with mild, moderate, or severe AD. (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 27, 2023 Category: Neurology Source Type: research
Recognition and Practice of Hypopituitarism After Traumatic Brain Injury and Subarachnoid Hemorrhage in Japan: A Survey
ConclusionsThe level of awareness of hypopituitarism post-TBI/SAH was lower among Japanese neurosurgeons than among endocrinologists. Educational programs and detailed guidance for the diagnosis and treatment of hypopituitarism post-TBI/SAH are warranted. (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 24, 2023 Category: Neurology Source Type: research
Effectiveness and Safety of Teriflunomide in Relapsing –Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
ConclusionTeriflunomide improves psychological aspects of HRQoL and maintains low levels of fatigue and depression. Treatment with teriflunomide over 2 years is effective in reducing ARR and disability progression. (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 20, 2023 Category: Neurology Source Type: research
Evaluating Perceived Fatigue within an Adult Spinal Muscular Atrophy Population
ConclusionsThis was the first use of more than two fatigue questionnaires simultaneously in SMA. The lack of a consistent relationship between SMA severity and fatigue levels was surprising. This may be related to the lack of specificity of the instruments for this population. An SMA-specific scale is needed to evaluate differences in fatigue impact across the SMA population. (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 19, 2023 Category: Neurology Source Type: research
Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit
AbstractA summit held March 2023 in Scottsdale, Arizona (USA) focused on the intronic hexanucleotide expansion in theC9ORF72 gene and its relevance in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS; C9ORF72-FTD/ALS). The goal of this summit was to connect basic scientists, clinical researchers, drug developers, and individuals affected by C9ORF72-FTD/ALS to evaluate how collaborative efforts across the FTD-ALS disease spectrum might break down existing disease silos. Presentations and discussions covered recent discoveries in C9ORF72-FTD/ALS disease mechanisms, availability of disease biomarkers and r...
Source: Neurology and Therapy - October 17, 2023 Category: Neurology Source Type: research
Association Between Serum Neurofilament Light Chain and Cognitive Performance Among Older Adults in the United States: A Cross-Sectional Study
ConclusionIn this sample of an American elderly population, higher sNfL levels are correlated with lower cognitive performance. Our findings suggest that sNfL may become a potential screening tool for early prediction and confirmation of cognitive damage. (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 16, 2023 Category: Neurology Source Type: research
Cost-Effectiveness of Tonic Motor Activation (TOMAC) Therapy for Patients with Restless Legs Syndrome: An Exploratory Analysis
Conclusion Based on this exploratory analysis of published trial data, TOMAC therapy appears to offer meaningful improvements in patient health-related quality at net costs that render it a cost-effective intervention. Further analyses are warranted. (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 12, 2023 Category: Neurology Source Type: research
No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]
AbstractThe emergence of high-efficacy therapies for multiple sclerosis (MS), which target inflammation more effectively than traditional disease-modifying therapies, has led to a shift in MS management towards achieving the outcome assessment known as no evidence of disease activity (NEDA). The most common NEDA definition, termed NEDA-3, is a composite of three related measures of disease activity: no clinical relapses, no disability progression, and no radiological activity. NEDA has been frequently used as a composite endpoint in clinical trials, but there is growing interest in its use as an assessment tool to help pat...
Source: Neurology and Therapy - October 11, 2023 Category: Neurology Source Type: research
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson ’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
(Source: Neurology and Therapy)
Source: Neurology and Therapy - October 10, 2023 Category: Neurology Source Type: research
Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer ’s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion
DiscussionPassive immunotherapy in AD is largely dominated by anti-amyloid antibodies, which are more numerous and more advanced in the pipeline. Lecanemab, donanemab and aducanumab are distinguished by their relative efficacy in terms of cognitive and functional evaluation but also by a decrease in amyloid and tau proteins in the brain. These three molecules have in common that they bind to N-terminal ends of amyloid fibrils and plaques. The findings of their studies raise the question of which criteria to apply when choosing which patient will receive them when marketed, such as the apoliprotein E gene ’s fourth allele...
Source: Neurology and Therapy - October 9, 2023 Category: Neurology Source Type: research
Predicting of Mechanical Ventilation and Outcomes by Using Models and Biomarker in Guillain-Barr é Syndrome
ConclusionsmEGOS scores predicted the outcomes of GBS patients in China, and EGRIS score predicted the need for mechanical ventilation in these patients. Albumin level at admission correlated well with disease severity and outcomes. (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 4, 2023 Category: Neurology Source Type: research
Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE
ConclusionsThese are the first consensus recommendations for the UAE that address the use of CGRP-based therapies in the treatment and management of migraine, integrating both clinical evidence and medical expertise to enhance clinical judgment and decision-making. (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 4, 2023 Category: Neurology Source Type: research
Identification of miRNAs Involved in Intracranial Aneurysm Rupture in Cigarette-Smoking Patients
ConclusionOur study indicated that smoking significantly altered the plasma miRNA profile in patients with IA. The expression of miR-574-5p, miR-151a-3p, and miR-652-3p correlated with aneurysm parameters, which may play a significant role in the formation and rupture of IA. (Source: Neurology and Therapy)
Source: Neurology and Therapy - October 4, 2023 Category: Neurology Source Type: research
Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
AbstractCladribine tablets (CladT) is a highly active oral disease-modifying therapy (DMT) for the management of relapsing multiple sclerosis (RMS). CladT acts as an immune reconstitution therapy, in that two short courses of treatment 1 year apart have been shown to suppress disease activity for a prolonged period in most patients, without need for continued DMT. Each course of CladT induces a profound reduction in B lymphocytes that recovers over months, and serious lymphopenia (Grade 3–4) is uncommon. Smaller reductions in le vels of T lymphocytes occur slightly later: on average, these remain within the normal rang...
Source: Neurology and Therapy - August 23, 2023 Category: Neurology Source Type: research
